CNS Pharmaceuticals Files S-1 with SEC

TL;DR

CNS Pharma just filed an S-1, looks like they're gearing up for a stock offering.

AI Summary

CNS Pharmaceuticals, Inc. filed an S-1 registration statement with the SEC on April 14, 2025. The company, incorporated in Nevada, is in the pharmaceutical preparations industry and is headquartered in Houston, Texas. This filing indicates a potential offering of securities, though specific details on the offering size or terms are not yet provided in this excerpt.

Why It Matters

This S-1 filing signals CNS Pharmaceuticals' intent to raise capital through a public offering, which could fund its drug development pipeline and future operations.

Risk Assessment

Risk Level: medium — S-1 filings often precede stock offerings, which carry inherent market and execution risks for early-stage companies.

Key Numbers

• 2834 — SIC Code (Identifies the company's industry as Pharmaceutical Preparations.)
• 12/31 — Fiscal Year End (Indicates the end of the company's financial reporting year.)

Key Players & Entities

• CNS Pharmaceuticals, Inc. (company) — Registrant
• John Climaco (person) — Chief Executive Officer
• 20250414 (date) — Filing Date
• 333-286529 (dollar_amount) — SEC File Number

FAQ

From the Filing

0001683168-25-002548.txt : 20250414 0001683168-25-002548.hdr.sgml : 20250414 20250414170116 ACCESSION NUMBER: 0001683168-25-002548 CONFORMED SUBMISSION TYPE: S-1 PUBLIC DOCUMENT COUNT: 21 FILED AS OF DATE: 20250414 DATE AS OF CHANGE: 20250414 FILER: COMPANY DATA: COMPANY CONFORMED NAME: CNS Pharmaceuticals, Inc. CENTRAL INDEX KEY: 0001729427 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences EIN: 822318545 STATE OF INCORPORATION: NV FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: S-1 SEC ACT: 1933 Act SEC FILE NUMBER: 333-286529 FILM NUMBER: 25836638 BUSINESS ADDRESS: STREET 1: 2100 WEST LOOP SOUTH STREET 2: SUITE 900 CITY: HOUSTON STATE: TX ZIP: 77027 BUSINESS PHONE: 1-800-946-9185 MAIL ADDRESS: STREET 1: 2100 WEST LOOP SOUTH STREET 2: SUITE 900 CITY: HOUSTON STATE: TX ZIP: 77027 S-1 1 cns_s1.htm FORM S-1 CNS Pharmaceuticals, Inc. S-1 false 0001729427 0001729427 2025-04-14 2025-04-14 iso4217:USD xbrli:shares iso4217:USD xbrli:shares As filed with the Securities and Exchange Commission on April 14, 2025.   Registration No. 333-               UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549     FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933   CNS Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Its Charter)   Nevada 2834 82-2318545 (State or Other Jurisdiction of Incorporation or Organization) (Primary Standard Industrial Classification Code Number) (I.R.S. Employer Identification Number)   2100 West Loop South , Suite 900 Houston , TX 77027 (800) 946-9185 (Address, Including Zip Code, and Telephone Number, Including Area Code, of Registrant’s Principal Executive Offices)   Mr. John Climaco Chief Executive Officer 2100 West Loop South, Suite 900 Houston, TX 77027 (800) 946-9185 (Name, Address, Including Zip Code, and Telephone Number, Including Area Code, of Agent For Service)   Copies to:   Cavas S. Pavri Johnathan Duncan ArentFox Schiff LLP 1717 K Street NW Washington, DC 20006 Telephone: (202) 724-6847 Fax: (202) 778-6460 Ron Ben-Bassat Eric Victorson Sullivan & Worcester LLP 1251 Avenue of the Americas New York, NY 10020 Telephone: (212) 660-3000   Approximate date of commencement of proposed sale to the public: As soon as practicable after the effective date of this Registration Statement.   If any of the securities being registered on this form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933, check the following box. ☒   If this form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐   If this form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐   If this form is a post-effective amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐   Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act:   Large accelerated filer ☐ Accelerated filer ☐ Non-accelerated filer ☒ Sm